Category: Interviews

Vittorio Sebastiano is an Associate Professor (Research) of Obstetrics and Gynecology at Stanford University and one of the most prominent scientists in the emerging field of cellular reprogramming. He is also co-founder and Scientific Advisory Board Chairman of Turn Biotechnologies, a cellular rejuvenation company based on the research done in Sebastiano’s Stanford lab. Turn recently...

We have written extensively about VitaDAO, a collective dedicated to community-governed, decentralized drug development. Probably the fastest and cheapest way to get geroprotective drugs to the market is by repurposing existing drugs, such as rapamycin, metformin, and acarbose. These drugs cost next to nothing, have a known safety record, and have shown a lot of...

Professor João Pedro de Magalhães leads the Genomics of Ageing and Rejuvenation Lab at the Institute of Inflammation and Ageing in the University of Birmingham. He is also CSO of YouthBio Therapeutics, a US-based biotech company that develops rejuvenation gene therapies based on partial reprogramming by Yamanaka factors. Last year, he co-authored The hoverfly and...

Richard A. Miller is a Professor of Pathology at the University of Michigan and the Director of Michigan's Paul F. Glenn Center for Biology of Aging Research. He is also a driving force behind the ITP, the Interventions Testing Program, created in the early 2000s to study the effect of various drugs on lifespan in...

In a recent press release, YouthBio Therapeutics announced that it has left stealth mode. YouthBio is a self-proclaimed longevity biotech company with a focus on developing gene therapies that reverse the epigenetic alterations that cause us to age. The company is hoping to reverse cellular aging in people through partial cellular reprogramming. This approach reverses...

Dr. Sajad Zalzala, co-founder of AgelessRx, prescribes naltrexone for a variety of conditions and is currently enrolling patients in clinical trials for its effectiveness against the lingering effects of COVID-19 as well as for longevity. We caught up with him to discuss the progress in this area. For the people who aren't familiar with low-dose...